fda glp-1 compounding warning letters september 2025 Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines FDA Targets GLP-1 and Peptide

Could semaglutide cause depression or anxiety

Learn about the benefits and practical steps for transitioning patients from GLP-1 RAs to dual GLP-1/GIP receptor agonists, such as tirzepatide, to improve glycemic control in adults with type 2 diabetes.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a cornerstone in the treatment of diabetes and obesity and have emerged as a promising option for other metabolic disorders, including hepatic steatosis

The Revolutionary Role of GLP-1 Agonists and SGLT-2 Inhibitors in Managing Diabetes and Chronic Kidney Disease Shankar Chakkera, Elizabeth J

GLP-1 receptor agonists have demonstrated significant weight loss results in clinical trials, with patients losing 15-22% of body weight over 68 weeks